Evidence map›Paper›PMID 30138436›Full record

ArticlePloS one2018

Expression of immunohistochemical markers in non-oropharyngeal head and neck squamous cell carcinoma in Ghana.

Osei Owusu-Afriyie, W K B A Owiredu, Kwabena Owusu-Danquah, Christine Komarck, Susan K Foltin, Rita Larsen-Reindorf, Emmanuel Acheampong, Solomon E Quayson, Mark E Prince, Jonathan B McHugh and 3 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Osei Owusu-AfriyieDepartment of Molecular Medicine, School of Medical Science, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.ORCID 0000-0002-7400-2952
W K B A OwireduDepartment of Molecular Medicine, School of Medical Science, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Kwabena Owusu-DanquahDepartment of Medical laboratory technology, Faculty of Allied Health, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Christine Komarck
Susan K Foltin
Rita Larsen-ReindorfDirectorate of Dental, Eye, Ear, Nose & Throat, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Emmanuel AcheampongDepartment of Molecular Medicine, School of Medical Science, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Solomon E QuaysonDepartment of Pathology, University of Ghana Medical School, Accra, Ghana.
Mark E Prince
Jonathan B McHugh
Peter DonkorDepartment of Maxillofacial Surgery, Dental School, KNUST, Kumasi, Ghana.
Sofia D Merajver
J Chad Brenner
Kwame Nkrumah University of Science and Technology · GHKomfo Anokye Teaching Hospital · GHUniversity of Ghana · GH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHead and neck cancers include carcinomas of the oral cavity, larynx, sinonasal tract and nasopharynx. Studies on molecular expression of prognostic tumour markers in Ghana are scarce. The purpose of this study was to determine the expression of p53, p16, EGFR, Cyclin-D1 and HER2 among patients with non-oropharyngeal head and neck squamous cell carcinoma (HNSCC). METHODOLOGY: Tissue microarrays from 154 histologically confirmed non-oropharyngeal HNSCC at the Komfo Anokye Teaching Hospital from 2006-2014 were constructed using duplicate cores of representative and viable areas from tumours. Expression of EGFR, p53, p16, Cyclin-D1 and HER2 was evaluated using immunohistochemistry.

resultsFor non-oropharyngeal HNSCC, majority of the cases (66.2%; 102/154) had stage IV disease. EGFR was the most expressed molecular marker (29.4%; 25/85) followed by p53 (24.0%; 29/121), p16 (18.3%; 23/126) and Cyclin-D1 (10.0%; 12/120). HER2 was not expressed in any of the cases. There was a significantly (p = 0.022) higher expression of Cyclin-D1 in tumours of the oral cavity (19.6%; 9/46) than in those of the larynx (4.7%; 2/43) and nose (3.2%; 1/31). Tumours in stages I-III were more frequently positive for p16 (28.6%; 12/42) than tumours in stage IV (13.1%; 11/84).

conclusionExpression of p53, EGFR, p16 and Cyclin-D1 in non-oropharyngeal HNSCC in Ghana is largely similar to what has been reported in published studies from other countries.

Indexed as

Up-RegulationAdolescentAdultAgedAged, 80 and overBiomarkers, TumorCyclin D1Cyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p18Erb-b2 Receptor Tyrosine KinasesErbB ReceptorsFemaleGene Expression Regulation, NeoplasticGhanaHead and Neck NeoplasmsHumansBiomarkers, TumorCCND1 protein, humanCDKN2A protein, humanCyclin D1Cyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p18EGFR protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesErbB ReceptorsTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID30138436
PMCPMC6107249
OpenAlexW2888733075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.